Recce secures Chinese patent as it targets superbugs with new anti-infectives

Recce Pharmaceuticals secures patent acceptance in China for synthetic anti-infectives as it targets growing global health problem of antibiotic-resistant superbugs.

Recce has secured patent acceptance in China for its anti-infectives. Pic via Getty Image

• Recce secures patent acceptance in China for anti-infectives

• Acceptance strengthens the company’s global patent portfolio

• Recce tackling global health problem of antibiotic-resistant superbugs

 

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health problem of antibiotic-resistant superbugs.

Recce Pharmaceuticals (ASX:RCE) said it had received a notice of acceptance from the China National Intellectual Property Administration, granting protection under Patent Family 4, which extends to 2041.

This acceptance strengthens the global patent portfolio for the developer of a new class of synthetic anti-infectives and supports its push into China’s fast-growing pharmaceutical market, the second largest in the world.

China has an antibiotic market valued at ~US$4.09 billion, projected to grow at a 5.7% CAGR from 2025 to 2030.

The company said the China patent claims relate most notably to:

• The process for preparation of RECCE anti-infectives
• Use of R327/R529 for the treatment of disease, particularly bacterial and viral infections
• Validation from studies in:
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Diabetic Foot Infections (DFI)
  • Burn wounds
  • Lung infections (including ventilator-associated and hospital-acquired pneumonia)
  • Urinary tract infections
  • Gonorrhoea
  • Influenza and SARS-CoV-2

• Administration methods, including oral, inhalation, transdermal, or injection (intravenous, intramuscular, or into the bloodstream)
• Optional formulations such as aerosol, gel, topical foam, ointment, or impregnated dressings for application to skin or mucous membranes (transdermal or transmucosal delivery)

Tackling global problem of antibiotic resistance

Recce is developing a new class of synthetic anti-infectives to tackle the global health threat of antibiotic-resistant superbugs.

Its anti-infective pipeline is designed to target urgent, unmet medical needs using its proprietary technology.

Its patented, broad-spectrum anti-infectives pipeline includes:

• R327 – Intravenous and topical therapy for serious Gram-positive and Gram-negative bacterial infections, including their superbug forms
• R435 – Orally administered therapy for bacterial infections
• R529 – Targeting viral infections

Its compounds feature multi-layered mechanisms of action, offering potential to overcome bacterial and viral resistance – one of the biggest challenges in modern medicine.

The World Health Organization has added R327, R435 and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.

The US Food and Drug Administration (FDA) has granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval.

R327 is also featured in The Pew Charitable Trusts’ Global Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate currently in development.

Recce fully owns its automated manufacturing facility, which supports ongoing clinical trials.

Watch more from RCE: Recce partners with the US Army

Growing patent portfolio

The newly accepted Chinese patent adds to existing Family 4 patent approvals in Australia, Canada, Israel and Japan, strengthening Recce’s global intellectual property position.

The company has further Patent Cooperation Treaty (PCT) submissions in various stages of review or allowance.

“This patent will broaden our patent portfolio for Family 4 into the second-largest pharmaceutical market in the world,” CEO James Graham said.

“We thank the China National Intellectual Property Administration for their formal recognition of the technical advantages of Recce’s new class of anti-infectives.”

This article was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as Recce secures Chinese patent as it targets superbugs with new anti-infectives